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Short summary 
PrEP use concentrated during time periods of condomless sex has the potential to substantively 
impact HIV incidence and to be cost-effective in the example setting of KwaZulu-Natal, South Africa.    
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Abstract (200 words) 
Introduction:  Oral pre-exposure prophylaxis (PrEP) in the form of tenofovir-disoproxil-
fumarate/emtricitabine is being implemented in selected  sites in South Africa.  Addressing 
outstanding  questions on PrEP cost-effectiveness can inform further implementation.   
Methods: We calibrated  an individual-based model to KwaZulu-Natal to predict the impact and 
cost-effectiveness of PrEP, with use concentrated in periods of condomless sex, accounting for 
effects on  drug resistance.   We consider (i) PrEP availability for adolescent-girls-and-young-women 
(aged 15-24; AGYW) and female sex workers (FSW), and (ii) availability for everyone aged 15-64.  Our 
primary analysis represents a level of PrEP use hypothesized to be attainable by future PrEP 
programmes.   
Results: In the context of PrEP use in adults aged 15-64 there was a predicted 33% reduction in 
incidence, and 36% reduction in women aged 15-24.   PrEP was cost effective, including in a range of 
sensitivity analyses,  although with substantially reduced (cost) effectiveness under a policy of ART 
initiation with efavirenz- rather than dolutegravir-based regimens due to PrEP undermining ART 
effectiveness by increasing HIV drug resistance.   
Conclusions: PrEP use concentrated during time periods of condomless sex has the potential to 
substantively impact HIV incidence and be cost-effective.    
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Introduction 
Despite declining  incidence, HIV remains a major public health challenge in South Africa.  The roll-
out of oral pre-exposure prophylaxis (PrEP) of tenofovir disoproxil fumerate (TDF) and emtricitabine 
(or lamivudine) to further reduce HIV incidence began with female sex workers (FSW), men who 
have sex with men (MSM) and adolescent girls and young women (AGYW).   Model-based analyses 
are increasingly used to inform allocation of limited resources [1,2].  Cost-effectiveness studies of 
PrEP, mainly conducted before the current universal eligibility for antiretroviral therapy (ART), have 
cast doubt over its cost-effectiveness, in South Africa as well as elsewhere [3-12].  There has, 
however, been relatively little attention given to considering that people might in practice 
concentrate their PrEP use only during periods of condomless sex. In addition, there is a risk of 
taking PrEP while unknowingly having HIV, due to starting PrEP when already infected with HIV 
(caused by <100% HIV test sensitivity or due to being in the primary infection window period), or  
becoming infected while taking PrEP, due to sub-optimal adherence, less than 100% PrEP efficacy, or 
infection with PrEP drug resistant virus.  Use of PrEP in people with HIV is associated with a risk of 
resistance to lamivudine or emtricitabine and TDF which are also used as part of 1st line ART [13].  
Consequently, there is a risk that efficacy of ART is undermined, with  further transmission of drug 
resistant virus [13].   While most cost-effectiveness evaluations have not explicitly taken this into 
account, modelling studies have suggested that resistance concerns should not preclude the use of 
PrEP [14-16].  The risk of resistance emerging is influenced by the length of time people with HIV 
stay on PrEP  and hence by the frequency of HIV testing in people on PrEP.   The WHO recommend 
three monthly testing for  PrEP  users [17].  Less frequent testing may improve retention on PrEP and 
reduce the cost of PrEP delivery but would have the disadvantage of extending the period in which 
people inadvertently take PrEP while having HIV. 
With these considerations in mind we present an updated assessment of the cost-effectiveness of 
oral PrEP with tenofovir disoproxil fumarate and emtricitabine in the context of the KwaZulu-Natal 
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(KZN) province of South Africa, a province characterised by particularly high prevalence of HIV [18-
22].  
 
Methods 
We updated a previously described individual-based model of HIV transmission, progression and the 
effect of ART[23,24] calibrating to the KZN epidemiological context, and undertook 500 model runs 
which ĂƌĞƌĞĨĞƌƌĞĚƚŽĂƐ “ƐĐĞŶĂƌŝŽƐ ? ?   Each time the model is run it simulates data in 3-monthly 
time steps on whether the person has an on-going primary condomless sex partner, the number of 
other condomless sex partners, HIV acquisition and, in people with HIV, viral load, CD4 count, use of 
specific ART drugs (.e.g. use of TDF-lamivudine-efavirenz as 1st line regimen up to 2019), adherence, 
resistance and risk of HIV-related death.  Details of the model and how it was calibrated to data from 
KZN are described in the Appendix.   The model was programmed in SAS 9.4 (SAS Institute, North 
Carolina).   
We considered  scale up of PrEP implementation from 2017 in either (i) FSW having multiple 
condomless sex partners (women who had >5 short-term condomless sex partners in a 3 month 
period in the past year) and adolescent girls and young women (AGYW; defined as women aged 15-
24; PrEP-for-AGYW/FSW), or  (ii) all men and women aged 15-64 (PrEP-for-all).  We refer to these as 
ƚǁŽĂůƚĞƌŶĂƚŝǀĞ “ƉŽůŝĐŝĞƐ ? ?ĂŶĚǁĞĐŽŵƉĂƌĞƉƌĞĚŝĐƚĞĚŽƵƚĐŽŵĞƐŽĨƚŚĞƐĞƚǁŽƉŽůŝĐŝĞƐǁŝƚŚŶŽWƌW
introduction.   
Parameter values relating to many aspects of PrEP are uncertain and some will likely vary between 
populations and ƐĞƚƚŝŶŐƐ ?tĞƐĞƚŽƵƚďĞůŽǁŽƵƌ “ƉƌŝŵĂƌǇĂŶĂůǇƐŝƐ ?ĂƐƐƵŵƉƚŝŽŶƐ ?ǁĞĞǆƉůŽƌĞ
variations in these assumptions in sensitivity analyses.   Our primary analysis involves relatively high 
use of PrEP concentrated in periods of condomless sex which is hypothesized to be potentially 
attainable by future PrEP programmes that have learned from experiences, rather than the current 
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status of programmes.   We assume PrEP is offered to people who have at least one condomless sex 
short-term partner in a 3 month period, or a condomless sex on-going primary partner who is 
diagnosed with HIV but not taking ART,  and that individuals who initiated PrEP only take PrEP 
subsequently in 3 month periods in which they have at least one such condomless sex partner.   We 
assume that the 1st-line ART regimen in use in new ART initiators will be dolutegravir-lamivudine-
TDF in all adults from 2019 onwards, given the strong recommendation from WHO to use this 
regimen [26].   Results for intermediate outcomes such as HIV incidence are shown over the 20 years 
(2018-2037).  The primary population health outcome measure was disability-adjusted life-years 
(DALYs), which is a generic measure that captures both premature mortality and morbidity.  Our 
model allows direct calculation of DALYs for each individual which can then be summed.   Disability 
weights are based on Salomon et al[25].  DALYs and costs are compared over up to 50 years, 
allowing the effects of HIV prevention to play out in terms of DALYs averted in those for whom 
infection in earlier life was averted. 
   
The PrEP adherence level for an individual, quantified on a scale of 0-100% is the proportion of the 
drug target level that is attained for episodes of condomless sex in a given 3-month period.  We 
assume an average adherence level per individual, but with within-person variability between 3 
month periods.  We further assume that 50% of adolescents and young people aged 15-24 years will 
be half as likely to adhere to PrEP compared to the rest of the population[27].   When providing 
PrEP-for-AGYW/FSW the assumptions result on average in 12%  of people on PrEP with <50% 
adherence , 33% with 50-79% adherence and 55% with >80% adherence.   The corresponding values 
for PrEP-for-all are 10%, 28% and 62%.  PrEP efficacy, defined as the percent reduction in risk of HIV 
acquisition from a given HIV-positive condomless sex partner with non-resistant virus under 100% 
PrEP adherence is assumed to be 95%.  PrEP effectiveness (what is measured in real life conditions) 
is assumed to be proportional (0.95-fold) to the PrEP adherence level, so in a person with current 
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PrEP adherence of 80% the current effectiveness would be 0.95x80% = 76%.  Given the adherence 
distribution, average effectiveness as implemented was 70% for PrEP-for-AGYW/FSW (i.e. average 
70% protection from each infected condomless partner in a 3 month period, 73% for PrEP-for-all), 
which compares with effectiveness estimates of 75% and 62%, respectively, in the Partners PrEP and 
TDF2 studies[28,29[.  We also assume that 15% of 15-64 year olds who are not FSW (and 5% of FSW) 
will not consider starting PrEP even if eligible.  Amongst those who would consider PrEP and for 
whom the condomless sex criteria are met, there is a 50% additional probability of being tested for 
HIV in each 3 month period (beyond background rates of testing); for those who test as HIV negative 
we assume an 80% chance that PrEP is initiated.  After stopping PrEP due to having one or more 3 
month periods with no condomless sex partners, PrEP can be restarted (with 95% probability) if the 
person tests HIV negative and again has condomless sex partners.  Continuation of PrEP involves 3-
monthly HIV testing.  We consider that people may choose to stop PrEP despite condomless sex 
criteria being met (3% probability of discontinuation per 3 months, 20% chance of resumption per 3 
month period of the condomless sex criteria being met).    There is assumed to be no increases in 
condomless sex in the population as a result of PrEP being introduced.  As mentioned, we recognise 
that in the early stages of PrEP roll-out in sub-Saharan Africa these levels of PrEP uptake and 
persistence of use have not been attained[30], but hypothesize that these are achievable as 
implementation lessons are learned[31], and we wished to explore the potential of PrEP, conditional 
on programmes being able to achieve our implementation conditions.   
PrEP is assumed to have 50% efficacy  against a virus containing both M184V and K65R mutations 
(conferring resistance to lamivudine/emtricitabine and TDF respectively) but fully efficacious (i.e. 
efficacy = 95%) otherwise.  We explored other assumptions in sensitivity analysis, including that 
K65R mutation confers reduced efficacy regardless of presence of the M184V mutation.      Our 
primary assumptions result in outputs of resistance emergence for persons who inadvertently take 
PrEP having been infected with HIV of mean 38% and 7% with M184V and K65R respectively by 3 
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months of infection[13,32].   We assume that voluntary medical male circumcision (VMMC), HIV-
testing and ART initiation given HIV diagnosis all remain constant at the 2017 rate into the future.   
Costs were estimated from the provider perspective, the South African government, on the basis of 
resource use due to PrEP (e.g. clinic visits, PrEP use and HIV tests) as well as subsequent healthcare 
interventions (ART and treatment of HIV-related diseases) and associated unit costs at relevant 
South African public-sector prices for 2017[33,34] and converted to in United States (US) dollars at 
an exchange rate of 13.6 ZAR/USD (Appendix page 7).   The modelled cost per year for a person on 
PrEP is US$136 (US$36 for 4 3-monthly HIV tests as recommended, US$40 for 4 clinic visits and 
laboratory costs and demand generation, US$60 for PrEP drugs (regardless of PrEP adherence)) 
[30,33,34].  Our assumptions regarding unit costs result in a mean cost of clinical care (including ART 
costs) per year per person with HIV in care (in 2017) of US $367 in the South African setting.   
In the cost-effectiveness analysis, both costs and health outcomes were discounted at 3% per 
annum, with a 7% local discount rate based on the South African Reserve Bank repurchase rate used 
in sensitivity analysis[35].  We assess cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐƵƐŝŶŐĂŵĞĂƐƵƌĞĐĂůůĞĚ “ŶĞƚ>zƐ ? ?ǁŚŝĐ
account for the opportunity costs of health benefits foregone when an intervention is delivered as 
well as the health benefits, by use of the cost-effectiveness threshold, and are calculated as 
DALYs+costs/cost-effectiveness threshold.  Incremental net DALYs show the difference between the 
health generated with the policy (compared with the no PrEP policy) and the health which would 
have been generated elsewhere in the healthcare system if the required resources were instead 
used for alternative purposes.  The policy with the lowest net DALYs incurred is the one that would 
be selected as the cost-effective policy choice with the common approach using incremental cost-
effectiveness ratios.   We use a cost-effectiveness threshold of $750, as this is approximately the 
cost-per-life-year-averted of HIV interventions at the borderline for inclusion within the South 
African HIV Investment Case that prioritizes use of the national HIV budget on the basis of 
intervention cost-effectiveness[36].  We therefore adopt an opportunity-cost based assessment of 
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cost-effectiveness, rather than using GDP-per-capita-based thresholds that are now recognised as 
being too high, especially for middle-income countries like South Africa[36-38[.    
 
 
Results 
The HIV epidemic and programmatic characteristics estimated by the model for KZN in 2017 and 
comparable observed data are shown in Table 1.   Table 2 shows, the predicted effect of the PrEP  
policies on a range of intermediate outputs relating to PrEP use over the next 20 years.   On average, 
around 8% of 15-24 year old females are projected to be on PrEP at any one point in time (i.e. in a 
given three month interval) over the next 20 years, with 1.3% (with PrEP-for-AGYW/FSW) and 3.4% 
(PrEP-for-all) of all people aged 15-64 (and 25% and 29% of FSW, respectively) on PrEP .  Of women 
age 15-24 who have one or more condomless sex partners in a 3 month period, the average 
proportion on PrEP at any one point in time over the next 20 years ŝƐ ? ?A? ?/Ŷ ? ?ǇĞĂƌƐ ?ƚŝŵĞ ?ƵŶĚĞƌ
the PrEP-for-AGYW/FSW policy 0.4% of all people would have taken PrEP in their lifetimes for over 5 
years, and 1.4% for the PrEP-for-all policy.   In the PrEP-for-all policy, 2.1% of people on PrEP are 
expected to be (unknowingly) infected with HIV (2.7% under PrEP-for-AGYW/FSW). 
PrEP policies lead to an increase in the  proportion of ART initiators having resistance to at least one 
drug in their 1st-line regimen (7% for the no PrEP policy, 22% for the policy of PrEP-for-all), which 
translates into 84% and 81%, respectively, of ART initiators who remain on ART at 1 year having viral 
suppression.    
There is predicted to be an average 25% decline in mean annual HIV incidence in women aged 15-24 
over 20 years (23% over 5 years/26% over 50 years; Figure 1) with PrEP-for-AGYW/FSW and a 36% 
(31%/35%) decline in HIV incidence in women aged 15-24  with the policy of PrEP-for-all, and a 33% 
(27%/36%) lower overall incidence in people aged 15-64 with PrEP-for-all.   In female sex workers 
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the predicted decline in incidence over 20 years is 33% (28%/35%) with PrEP-for-AGYW/FSW and 
43% (39%/43%) with PrEP-for-all.  The HIV prevalence for people age 15-49 in 20 (5 / 50) years time 
is predicted to be 23% (26%/22%) with no PrEP, 21% (26%/19%) with PrEP-for-AGYW/FSW and 17% 
(25%/14%) with PrEP-for-all.  With the rate of scale-up as indicated, the annual cost of PrEP over the 
first 3 years is $7.4m ($20.7m) in year 1 (2017-18), $9.5m ($25.3m) in year 2 (2018-2019), $10.4m 
($27.2m) in year 3 (2019-2020), $11.7m ($30.4m) in year 5 (2021-22) and $13.2m ($33.8m) in year 
10 (2026-27) for PrEP-for-AGYW/FSW (PrEP-for-all).    
Figure 2 shows that PrEP-for-all, while averting DALYs, is not expected to increase overall costs over 
the long term (50 years, at a 3% discount rate), suggesting that it is cost-effective.    However, given 
the cost increases in the early years of introduction, especially with the PrEP-for-all approach, any 
cost savings would only be realized over an extended time horizon.  We show the cumulative net 
DALYs averted over time expressed as a mean per year of the time horizon (Figure 2c)  W there is a 
cumulative net health benefit by 2034 (17 years from PrEP introduction) with PrEP-for-all, and by 
2039 (22 years after PrEP introduction) with PrEP-for-AGYW/FSW.    
Table 3 (and Appendix Table S1, page 3) summarizes the impact and cost-effectiveness of PrEP for 
our primary analysis, and then shows the effect of variations in many of the model assumptions.   As 
well as showing effects on DALYs, costs and net DALYs, we show effects on HIV incidence and, 
reflecting the impact of PrEP on acquisition and transmission of resistance, on virologic response to 
1st-line ART.   In the primary analysis (row 1), the PrEP-for-all policy  is the cost-effective policy choice 
(most net DALYs averted) in 100% of scenarios.   PrEP-for-all tended to remain cost-effective in most 
one-way sensitivity analyses, although quantitatively the net health benefit (net DALYs averted) was, 
as expected, lower with lower PrEP efficacy, adherence, uptake and less concentration of use around 
periods of condomless sex  
PrEP was not cost-effective if it leads to substantial increases in condomless sex amongst people on 
PrEP.  The continued use of efavirenz- rather than dolutegravir in ART initiators  would be predicted 
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to lead to a substantial reduction in overall PrEP effectiveness, due to increased drug resistance.  In 
this context of continuation of use of efavirenz in 1st line ART regimens, the response to first line ART 
would be predicted to be significantly reduced over the next 20 years with PrEP introduction.    Six 
monthly HIV testing for people on PrEP is predicted to be of similar effectiveness and cost 
effectiveness compared with 3 monthly testing.   
 
Discussion 
This modelling study suggests that PrEP use concentrated amongst people and periods of 
condomless sex has the potential to be highly  impactful on HIV incidence and  cost-effective in KZN.  
The  PrEP-for-all policy is predicted to have a substantially greater overall impact on incidence, and 
be more cost-effective than a policy of restricting PrEP availability to AGYW/FSW.  There is also 
predicted to be a greater impact on incidence in women aged 15-24  with PrEP-for-all than when 
PrEP use is restricted to  such women and FSW, due to the effects of a reduction in HIV prevalence in 
men.  A policy of PrEP-for-all may have advantages over policies which restrict by demographics as it 
removes any issues with eligibility and helps to avoid PrEP programmes potentially spotlighting and 
stigmatising groups of people.   
Cost-effectiveness of PrEP programmes remains subject to some uncertainty.  If PrEP use leads to 
significant increases in condomless sex episodes that are not covered by PrEP  it is unlikely to be 
cost-effective.  Cost effectiveness of PrEP is also related to whether its use is concentrated in periods 
of condomless sex, but even with less concentrated use of PrEP, so that there is one 3 month period 
of use when there is no risk for each 3 month period in which there is risk through condomless sex, 
PrEP remained cost effective.   However, if we assume that PrEP use is entirely unrelated to 
condomless sex (which perhaps seems  unlikely but remains possible ), it is not cost effective.   A 
major challenge for programmes is to achieve and maintain high levels of  PrEP use during periods of 
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condomless sex.   The impact and cost-effectiveness of PrEP is substantially dependent on the  
avoidance of use of efavirenz in 1st-line regimens compared with use of dolutegravir.  This is to 
avoid increases in NNRTI resistance, secondary to emergence of resistance to 
lamivudine/emtricitabine and TDF, which would be predicted to  lead to effects of ART being 
undermined.  In other work outside the context of PrEP we have considered the risks and benefits of 
this choice[47].   We found that PrEP with six monthly HIV testing has similar effectiveness and  cost-
effectiveness to three monthly testing but we see no compelling case to recommend less frequent 
testing than three-monthly.  PrEP impact and cost-effectiveness is influenced by the extent to which 
WƌWŚĂƐĞĨĨŝĐĂĐǇŝŶƉƌĞǀĞŶƚŝŶŐŝŶĨĞĐƚŝŽŶǁŚĞŶƚŚĞƉĂƌƚŶĞƌ ?ƐǀŝƌƵƐŚĂƐĚƌƵŐƌĞƐŝƐƚĂŶĐĞƚŽWƌWĚƌƵŐƐ ?
Continued monitoring of drug resistance is important. 
In our primary analysis the time point at which a net health benefit is achieved is 2034 with the PrEP-
for-all policy, and 2039 for the policy of PrEP-for-AGYW/FSW.   Policymakers will need to trade short-
term imposition of costs with longer-term health benefits and cost reductions as a result of HIV 
infections averted.  Short term costs and longer-term benefits are expected to be greater with PrEP-
for-all than PrEP-for-AGYW/FSW only.  The use of discount rates facilitates the comparison of costs 
and health effects occurring at different points through time, but the appropriate discount rates are 
uncertain.        
Programmes will need to innovate if they are to overcome the challenges of implementing PrEP as it 
has been modelled.  Self-report of risk is unreliable.  One approach would be to advise people to 
take daily PrEP for the next 3 months if they may have new sexual partners and are unsure about 
their ability to use condoms consistently with those new partners.  We note our assumption that 
periods of PrEP use around condomless sex last at least 3 months, which may be conservative and 
PrEP use may be further concentrated in practice into shorter periods than we have assumed.  We 
assume daily dosing during three month periods on PrEP, although dosing around sex acts may be 
feasible[48, 49].   A key challenge in the use of PrEP in Africa is the low reported levels of persistent 
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use [e.g. 50].  The reasons underlying this, and solutions to addressing those causes will need to be 
identified if effects of the magnitude we have modelled are to be realised.   
Limitations of our analysis, as for any cost-effectiveness analysis, include that it involves projection 
of the HIV epidemic and HIV programme over several years - we assume rates of VMMC, HIV-testing 
and ART initiation given HIV diagnosis remain constant, which is associated with uncertainty which 
we explored in sensitivity analyses.  We define a female sex worker as a woman who had over 5 
short-term condomless sex partners in a 3 month period over the past year and this is a relatively 
simple characterization.  We combined AGYW/FSW into one group although provision of PrEP to 
FSW is likely to be more cost-effective than provision to AGYW.  We do not model sex between men, 
although we would note that an added benefit of the policy of PrEP-for-all is that MSM would be 
able to access PrEP without having to state their sexuality should they wish.   We use a relatively 
long time step of 3 months which we consider should be adequate to accurately capture most 
effects but we cannot exclude the possibility that a shorter time step would reveal nuances that we 
missed.   Lastly, we focussed on KZN province and further analyses of other provinces would be 
needed to assess how generalizable our findings are across South Africa.   
 
Conclusions 
PrEP use concentrated during time periods of condomless sex has the potential to substantively 
impact HIV incidence and to be cost-effective.  Further research and monitoring are required to 
understand the effects of PrEP programmes, including on HIV drug resistance.   
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Table 1.  HIV epidemic and programmatic characteristics in 2017 (KZN, South Africa), based on 500 model runs. 
Characteristic Model  
(Median, 90% 
range)   
Examples of observed data (year)    
HIV prevalence: age 15- 49 (men and women combined) 
   
                             age 15-19 men / women                    
                             age 20-24 men / women           
      
                        female sex workers**  
27% (25%  W 29%) 
 
2.3% / 7.4%   
8.7% / 24.4% 
 
72% (60% - 84%)  
27% men and women (19.8% men, 33.0% women) (KZN, 2017) 22 
 
2.2% /  8.5% 21  (KZN 2012) 3.6%  / 5.3% (KZN 2017) 22 
10.0% / 25.5% 21 (KZN 2012) 7.8% / 18.1% (KZN 2017) 22 
age 15-24  7.6% / 22.3% (2014/2015) 20   
76% (2015) 39 
HIV incidence*: age 15- 49 (men and women combined) 
                             age 15- 24 women  
                             female sex workers** 
2.6 (1.9  W 3.2)   
3.6 (2.1  W 5.4) 
60 (28  W 109) 
3.3  (2012) 21 
1.5 women age 15-24, 0.93 women aged 15-49  (South Africa as a 
whole, 2017) 22 
Proportion of new infections from new / short term partners 51% (38% - 66%) no data identified 
Proportion of HIV positive people diagnosed 
 
 
83% (75% -  89%) 83% (2015) (South Africa 40);  84.9% (South Africa 22); 
76% (2013) (within KZN 41); 77%  men age 15-49, 90% women age 15-
49 22  KZN (2017) 
Proportion of diagnosed people who are on ART 76% (70% - 83%) 71% (South Africa 22) 
77%  men age 15-49, 79% women age 15-49 22  KZN (2017) 
Proportion of all HIV positive people with viral load < 1000 copies/mL 50% (44% -  57%) 55% in women, 42% in men (2014/15) (20 (< 400 copies/mL)) 
52% of HIV+ people are on ART with VL < 1000 (South Africa 22) 
67.5% of all HIV+ people, including people with VL 1000 not on ART 
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People age 15- 64 unless stated.  Population size 7.1 million, AGYW 1.1 million;   * (/100 person years)  ** Female sex workers defined as women having > 5  condomless 
sex partners in a 3 month period in past year; *** some people on ART with poor adherence do not report being on ART which affects comparison of model output with 
observed data.    
(KZN 22) 
Number of adults on ART 1,144,000 1,222,000 (2017) (personal communication, authors) 
Of people on ART, proportion with VL < 1000 cps/mL 82% (79% -  88%) 87% women, 84% men (2014/15) (20 < 400 copies / mL)***); 85% 
(2015) (< 400 copies/mL40)  ;  77%  men age 15-49, 89% women age 
15-49 22  KZN (2017) 
Of people who started ART 1 year ago and are still on ART, proportion with 
VL < 500 cps/mL  
80% (70% -  89%) no data identified 
Of people on ART with VL > 1000 cps/mL proportion  
with K65R  /  M184V mutation in majority virus 
64% (44% -  79%) /  
92% (85% -  95%) 
56%-60% (Africa) 42  
59%-71% (Africa) 42   
Proportion of all people with HIV who have viral load > 1000 copies/mL 
and carry M184V / K65R in majority virus. 
11% (7% - 14%) / 
7% (4% - 11%) 
no data identified 
Of people starting ART, proportion with NNRTI drug resistance  11% (5% - 17%) 14% 45,46 
Proportion of women who are FSW** 2.8% (0.9% -  4.7%) 0.4% -  4.3% urban areas in SSA 2006 43  0.9% 44 
Proportion of men age 15-64  (age 15-24) who are circumcised 35% (31% - 45%) 32% medically circumcised 22 
Cost of clinical care (including ART costs) per year per person with HIV in 
care (mean) 
$367 $240 (excluding inpatient costs) 34 
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Table 2.  Predicted effects of PrEP policies on use and intermediate health outcomes over 20 years (2017  W 2036)    
Outcome mean over 3 month periods 2017 - 2036 except 
where stated; (90% uncertainty range; 95% confidence 
interval*) 
No PrEP PrEP-for-AGYW/FSW PrEP-for-all 
Proportion of women age 15-24 on PrEP 0% 7.6%  (3.4% - 12.4%; 7.3% - 7.9%) 7.9% (3.5% - 12.7%; 7.6% - 8.2%) 
Proportion of people age 15-64 on PrEP  0% 1.3%  (0.6% - 2.0%; 1.3% - 1.3%) 3.4% (1.9% - 5.4%; 3.4% - 3.4%) 
In 2037, proportion of people age 15-64 ever taken PrEP 0% 13% (8% - 17%; 13% - 13%) 31%  (23% - 39%; 31% - 32%) 
Of women age 15-24 who have > 1 new condomless sex 
partner in a 3 month period, proportion on PrEP  
0% 37% (28% - 45%; 36% - 38%) 37%  (30% - 46%; 36% - 38%) 
Number of people on PrEP 0 103000  (49,000  W 159,000; 100,000 
 W 106,000) 
275,000 (151,000  W 444,000; 
266,000  W 284,000) 
Of people on PrEP, percent with (undetected) HIV & --- 2.7%  (1.0% - 5.1%; 2.6% - 2.8%)  2.1%  (0.8% - 3.4%; 2.0% - 2.2%) 
Of all people living with HIV,  percent on ART 75%  (68% - 80%; 75% - 75%) 76%  (70% - 81%; 76% - 76%) 79%  (73% - 84%; 79% - 79%) 
Of people starting ART, proportion with NNRTI drug resistance 9%  (4% - 14%;8% - 9%) 10%  (5% - 16%; 10% - 10%) 14%  (8% - 22%; 14% - 14%) 
Proportion of all people with HIV who have viral load > 1000 
cps/mL and carry M184V / K65R in majority virus. 
6%  (4% - 8%; 6% - 6%) /  
4%  (2% - 7%; 4% - 4%) 
7% (4% - 9%; 7% - 7%) /  
5% (2% - 7%; 5% - 5%) 
8%  (5% - 10%;8% - 8%) /  
6%  (3% - 9%; 6% - 6%) 
Of people starting ART, proportion with resistance to at least 
one drug in their 1st-line regimen  
7%  (4% -10%; 7% - 7%) 11%  (7% - 16%; 11% - 11%) 22%  (15% - 29%; 22% - 22%) 
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Of people who started ART 1 year ago and are still on ART, 
proportion with VL < 500 cps/mL 
84%  (78% - 89%; 84% - 84%) 83%  (77% - 89%; 82% - 83%) 81%  (75% - 88%; 81% - 81%) 
Of all people on ART, percent with viral load < 1000 copies/mL 91%  (89% - 94%; 91% - 91%) 91%  (89% - 94%; 91% - 92%) 91%  (89% - 94%; 90% - 91%) 
Of all people living with HIV,  percent with viral load < 1000 
copies/mL    
67%  (61% - 74%; 67% - 68%) 69%  (62% - 75%; 69% - 69%) 71%  (66% - 77%; 71% - 71%) 
Of adult population, proportion with HIV and viral load > 1000 
copies/mL 
10%  (8% - 13%; 10% - 10%) 10%  (7% - 12%; 10% - 10%) 8%   (6% - 10%; 8% - 8%) 
*(90% uncertainty range represent variability across scenarios (n=500) that are consistent with observed data used in calibration (likely largely due to different sexual 
behaviour patterns in different scenarios - they do not include uncertainty over uptake and persistence of PrEP use)).  95% confidence interval represents uncertainty in the 
mean due to stochastic uncertainty (i.e. this tends to zero with increasing number of model runs).   
& reasons for HIV infection in people on PrEP are (in order of importance): Infection on PrEP with drug resistant HIV, infection on PrEP with drug sensitive HIV due to fact 
that efficacy is 95% and not 100%, starting PrEP in primary infection, starting PrEP while HIV +ve due to < 100% sensitivity of HIV test. 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/jid
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/in
fd
is
/jiz
6
6
7
/5
6
8
0
5
8
8
 b
y
 J
 B
 M
o
rre
ll L
ib
ra
ry
, U
n
iv
e
rs
ity
 o
f Y
o
rk
 u
s
e
r o
n
 0
2
 J
a
n
u
a
ry
 2
0
2
0
Ac
ce
pte
d M
an
us
cri
pt
 
28 
 
Table 3.   Reduction in incidence, difference in response to 1st line ART, DALYs averted and net DALYs averted with policies of PrEP-for-AGYW/FSW and 
PrEP-for-all.  Variations in sensitivity analysis.    Mean over 50 years (20 years for HIV incidence@  and difference in response to 1st line ART++ ) and 95% 
confidence interval.     
 
Variation from primary analysis 
assumptions 
 
Reduction in Incidence 
(%)@ 
Difference in 
response to 1st line 
ART++ 
DALYs averted** 
 
Difference in cost (US$ 
million; compared with 
no PrEP) 
Net DALYs averted** 
(percent of scenarios in 
which PrEP policy is the 
cost-effective policy 
choice^. 
PrEP for 
FSW/AGYW* 
PrEP-for-
all 
PrEP for 
FSW/AGYW 
PrEP-for-
all 
PrEP for 
FSW/AGYW 
PrEP-for-
all 
PrEP for 
FSW/AGYW 
PrEP for 
all 
PrEP for 
FSW/AGYW 
PrEP-for-
all 
No variation (primary analysis) 25% 
(25, 26) 
33% 
(32, 33) 
-1% 
(-1, -1) 
-3% 
(-2, -3) 
9.6 
(9.0, 10.0) 
34.7 
(33.7, 35.7) 
-$5.1 
(-5.4,-4.8) 
-$15.0 
(-15.6, -14.4) 
16.3  
(0%) 
(15.3, 16.7) 
54.7 
(100%) 
(54.0, 
56.4) 
100% adherence when on PrEP s1 41% 
(39 42) 
48% 
(45, 50) 
-0% 
(0, 0) 
-2% 
(-2, -2) 
20.6 
(18.1, 23.1) 
58.0 
(51.6, 64.4) 
-$15.1 
(-17.0, -13.2) 
-$35.0 
(-38.9 -31.1) 
40.7  
(0%) 
(36.1, 45.3) 
105.6 
(100%) 
(94.9, 
116.3) 
PrEP efficacy 80% (primary analysis: 
95%)   s2 
20% 
(18, 22) 
27% 
(24, 29) 
-1% 
(-1, 0) 
-2% 
(-2, -2) 
6.3 
(4.5, 8.1) 
26.3 
(21.4, 31.2) 
-$1.2 
(-2.8, +0.4) 
-$5.2 
(-8.5, -1.9) 
7.8 
(5%) 
(4.6, 11.0) 
33.2  
(95%) 
(25.2, 
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41.2) 
Probability of re-starting PrEP during a 
period with condomless sex partner(s)+ 
having previously interrupted for a 
period with no new condomless sex 
partners 50% (primary analysis: 95%) o   
s3 
24% 
(22, 26) 
32% 
(29, 36) 
-0% 
(-1, 0) 
-2% 
(-2, -2) 
8.9 
(6.7, 11.1) 
32.2 
(27.0, 37.7) 
-$4.0 
(-5.9, -2.1) 
-$13.7 
(-17.9, -9.5) 
14.3  
(3%) 
(10.1, 18.5) 
50.1  
(97%) 
(40.6, 
59.6) 
Risk of stopping/interrupting PrEP per 3 
months (despite continuing to have 
new condomless sex partner(s)) 10% 
(primary analysis: 3%)  o   s4   
20% 
(17, 22) 
27% 
(25, 29) 
-2% 
(-1, -2) 
-1% 
(0, -1) 
6.5 
(5.2, 7.8) 
26.1 
(22.8, 29.3) 
 
-$3.2 
(-4.4, +2.0) 
-$11.2 
(-13.4, -9.0) 
10.8  
(0%) 
(8.3, 13.3) 
41.0 
(100%) 
(35.9, 
46.1) 
 
50% of people will not consider starting 
PrEP despite having condomless sex 
partner(s)+  (primary analysis: 15%)  o    
s23 
23% 
(21, 24) 
19% 
(18, 22) 
0% 
(-1, 0) 
-1% 
(-1, -1) 
6.9 
(5.1, 8.8) 
23.1 
(20.2, 26.0) 
-$4.8 
(-5.9, -3.7) 
-$11.4 
(-13.4, -9.2) 
13.3  
(0%) 
(10.6, 16.0) 
38.3 
(100%) 
(33.6, 
43.0) 
Lower PrEP uptake and retention (as 
reflected by simultaneous variations 
above indicated by  o)  s25 
17% 
(16, 18) 
14% 
(13, 15) 
0% 
(-1, 0) 
-1% 
(-1, -1) 
5.0 
(3.6, 6.4) 
16.6 
(15.0, 18.2) 
-$2.5 
(-3.3, -1.7) 
-$8.2 
(-9.0, -7.4) 
8.3  
(0%) 
(6.3, 10.3) 
27.5 
(100%) 
(25.5, 
29.5) 
Efavirenz as 1st-line ART in all (primary 
analysis:  dolutegravir as 1st line n all s8 
21% 
(20, 22) 
24% 
(22, 25) 
-5% 
(-5, -5) 
-14% 
(-14, -14) 
-0.8~~ 
(-2.7, 1.1) 
10.0 
(6.4, 13.6) 
+$1.6 
(+0.4, +2.8) 
+$0.9 
(-1.3, +3.1) 
-3.0~~ 
(6%) 
8.9  
(60%) 
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(-7.2, 0.2) (3.1, 14.7) 
PrEP has 0.5 fold lower efficacy against 
virus with k65r (regardless of presence 
of m184v)  s28 
25% 
(24, 27) 
33% 
(31, 35) 
-1% 
(-1, 0) 
-3% 
(-3, -2) 
9.2 
(7.9, 10.5) 
31.6 
(28.1, 35.1) 
-$4.6 
(-5.9,-3.3) 
-$13.6 
(-15.5, -11.7) 
15.3  
(1%) 
(13.4, 17.2) 
49.6  
(99%) 
(44.5, 
55.0) 
PrEP has zero efficacy against virus 
containing both M184V and K65R 
mutations  s22  
24% 
(23, 26) 
29% 
(26, 30) 
-1% 
(-1, -1) 
-4% 
(-4, -3) 
7.4 
(5.9, 8.9) 
25.4 
(22.0, 28.8) 
-$3.3 
(-4.8, -1.8) 
-$4.7 
(-8.3, -1.1) 
11.8  
(6%) 
(8.8, 14.8) 
31.7 
 (94%) 
(25.0, 
38.4) 
PrEP clinic visits and HIV testing 6 
monthly (primary analysis: 3 monthly)  
s9 
25% 
(24, 27) 
34% 
(32, 35) 
-1% 
(-1, 0) 
-3% 
(-3, -2) 
8.9 
(7.9, 9.9) 
32.9 
(30.0, 35.5) 
-$5.8 
(-6.7, -4.9) 
-$17.8 
(-19.7, -15.9) 
16.2  
(0%) 
(14.4, 18,0) 
56.6 
(100%) 
(51.0, 
61.2) 
HIV testing uses antigen/antibody tests 
(primary analysis: antibody only)&    
 
25% 
(23, 26) 
33% 
(31, 35) 
-1% 
(-1, 0) 
-2% 
(-2, -2) 
9.4 
(8.1, 10.7) 
35.9 
(33.3, 38.5) 
-$5.3 
(-6.2, -4.4) 
-$16.3 
(-18.1, -14.5) 
16.5  
(0%) 
(14.3, 18.7) 
57.6 
(100%) 
(53.2, 
62.0) 
People on PrEP have 2 fold increased 
numbers of condomless sex partners 
due to taking PrEP (primary analysis: no 
increase)    
16% 
(15, 17) 
15% 
(14, 16) 
-1% 
(-1, -1) 
-4% 
(-4, -4) 
-3.2~ 
-4.2, -2.2) 
4.9  
(2.9, 6.9) 
+$6.3 
(+5.5,+7.1) 
+$12.2 
(+10.8,+13.6) 
-11.7~~ 
(5%) 
(-13.4, -10.0) 
-11.3~~ 
(27%) 
(-14.7, -
6.9) 
One 3 month period of PrEP while no as primary as as primary as as primary as +$0.7 +$0.8 8.6  33.7   
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@ Reduction in incidence is shown over a shorter time period than 50 years as a mechanism of effect on DALYs is via reduction in new infections. ++ Difference in of people 
who started ART 1 year ago and are still on ART, proportion with VL < 500 cps/mL - differences are due to differences in drug resistance outcomes and this output is shown 
over a shorter time period than 50 years as drug resistance is a mechanism of effect on DALYs ;  * Reduction in incidence relates to AGYW only in relation to PrEP for AGW 
and to all age 15-64 for PrEP-for-all; ** DALYS and net DALYs averted in whole population (in 1000s; net DALYs based on cost-effectiveness threshold of $750); ^ in 
remainder of scenarios no PrEP introduction is the most cost-effective policy;  + or a period with a primary on-going condomless sex partner who is diagnosed with HIV but 
condomless sex is experienced (not 
even with a primary partner) for each 3 
month period of PrEP while having 
condomless sex partners+ (primary 
analysis: PrEP not used in 3 month 
periods with no new condomless sex 
partners).   uses base runs 
analysis 
 
primary 
analysis 
 
analysis primary 
analysis 
analysis primary 
analysis 
(-0.2, +1.6) (+0.4,+1.2) (4%) 
(7.9, 9.3) 
 
 
(95%) 
(31.9, 
35.5) 
 
7% discount rate (primary analysis: 3%) 
uses base runs 
as primary 
analysis 
as 
primary 
analysis 
as primary 
analysis 
as 
primary 
analysis 
2.7 
(2.5, 2.9) 
10.6 
(10.2, 11.0) 
 
-$0.3 
(-0.5, -0.1) 
-$1.8 
(+1.5, +2.1) 
3.1  
(2%) 
(2.8, 3.4) 
13.0  
(98%) 
(12.5, 
13.5) 
Plausible future reduced PrEP costs 
(four HIV tests per year $3 each, one 
annual PrEP clinic visit only, PrEP drug 
$35 = $57 per year) (primary analysis: 
$136 per year)  uses base runs 
as primary 
analysis 
as 
primary 
analysis 
as primary 
analysis 
as 
primary 
analysis 
as primary 
analysis 
as 
primary 
analysis 
-$8.5 
(-8.8, -8.2) 
-$24.5 
(-25.1, -23.9) 
20.9  
(0%) 
(19.2, 22.6) 
67.4 
(100%) 
(66.7, 
68/1) 
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off ART; & test cost assumed the same as antibody only test;  ~ DALYs not averted, ~~ net DALYs not averted.  # percentage of scenarios in which policy is cost-effective 
choice considering only no PrEP and PrEP for FSW
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Legends for Figures 
 
Figure 1.   Percent reduction in HIV incidence compared with no PrEP introduction (mean over 20 
years), with 95% confidence interval       and 90% uncertainty range            *.  (a) in women aged 15-
24;  (b) in people aged 15-64 
 
 
*90% uncertainty range represent variability across scenarios (n=500) that are consistent with observed data used in 
calibration (likely largely due to different sexual behaviour patterns in different scenarios they do not include uncertainty 
over uptake and persistence of use).  95% confidence interval represents uncertainty in the mean due to stochastic 
uncertainty (i.e. this tends to zero with increasing number of model runs).    
 
 
 
 
 
Figure 2.   Cost, DALY and net DALY outcomes over 50 year time horizon, 3% per annum discount 
rate. (a) Breakdown of costs according to policy (b) DALYs averted and increment in cost for 
alternative PrEP targeting policies;   PrEP-for-all is cost saving compared with no PrEP and compared 
with PrEP in FSW/AGYW (c)  Cumulative net DALYs averted per annum according to length of time 
horizon. 3% discount rate.  See appendix for similar figure but with 7% discount rate.   
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